Vaccitech to Present at the Barclays Global Healthcare Conference 2022
March 07 2022 - 8:00AM
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical
company engaged in the discovery and development of novel
immunotherapeutics and vaccines, today announced that the Company’s
Chief Executive Officer, Bill Enright, and Chief Financial Officer,
Georgy Egorov, will participate in a fireside chat at the Barclays
Global Healthcare Conference at 2:05 p.m. EDT on Tuesday, March 15,
2022, in Miami.
A live webcast of the presentation can be accessed through
the Events section of the Vaccitech website. Following
the live webcast, a replay will be available at the same
location.
About Vaccitech plcVaccitech (“the Company”) is
a clinical-stage biopharmaceutical company engaged in the discovery
and development primarily of novel immunotherapies for the
treatment of chronic infectious diseases, cancer and diseases where
the T cell arm of the immune system is believed to play an
important role. The company’s proprietary platforms include
modified simian adenoviral vectors (ChAdOx1 and ChAdOx2), other
viral vectors including the well-validated Modified Vaccinia Ankara
(MVA) and synthetic nano-particle technologies (SNAPvax™ and
Syntholytic™). The combination of different technologies in a mix
and match approach (heterologous prime-boost) consistently
generates significantly higher magnitudes of T cells compared with
other technologies and approaches. The company has a broad pipeline
of both clinical and preclinical stage therapeutic programs to
treat solid tumors, chronic viral infections, as well as a few
prophylactic viral vaccine programs. Vaccitech co-invented a
COVID-19 vaccine with the University of Oxford, now approved for
use in many territories and exclusively licensed worldwide to
AstraZeneca through Oxford University Innovation, or OUI. Vaccitech
is entitled to receive a share of all milestones and royalty income
received by OUI from AstraZeneca.
Vaccitech Media contacts:Katja Stout, Scius
Communications (EU)Direct: +44 (0)
7789435990Email: katja@sciuscommunications.com
Katie Larch / Robert Flamm, Ph.D., Burns McClellan, Inc.
(U.S.)Email: klarch@burnsmc.com / rflamm@burnsmc.com
Karim Saleh,
VaccitechEmail: karim.saleh@vaccitech.co.uk
Vaccitech (NASDAQ:VACC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaccitech (NASDAQ:VACC)
Historical Stock Chart
From Apr 2023 to Apr 2024